{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:04:54Z","timestamp":1790643894919,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening microangiopathic hemolytic anemia characterized by thrombocytopenia, hemolytic anemia, and ischemic organ damage. It is mainly caused by an autoreactive antibody directed at ADAMTS13. Immunotherapy is frequently associated with autoimmune complications in patients with cancer, but only three cases of TTP have been reported, none implicating single treatment with the anti\u2013programmed cell death receptor 1 ligand antibody nivolumab. We present the first identified and reported case of nivolumab-associated TTP in a 51-year-old woman with stage IIIc anal carcinoma who achieved complete response following chemoradiation and received adjuvant nivolumab as part of a randomized clinical trial. Twelve weeks into treatment, she presented with dark urine, progressive fatigue, and headache. TTP diagnosis was based on laboratory evidence of hemolytic anemia, thrombocytopenia, and ADAMTS13 activity of 9% associated with an inhibitor. She was treated with daily plasma exchange and oral prednisone and responded well to treatment, with platelet counts over 100 K\/cmm within 4\u2009days. We reviewed and summarized data from all reported cases of TTP associated with cancer immunotherapy. We provide guidance on identification and management of this devastating hematologic complication, focusing on the importance of early recognition, as most patients achieve complete recovery with appropriate treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>Thrombotic thrombocytopenic purpura (TTP) was originally excluded from previous reviews of hematologic immune-related adverse events; however, several cases have been reported in the past 2\u2009years in patients treated with either single agent or combination of cytotoxic T-lymphocyte\u2013associated antigen 4 and the programmed cell death receptor 1 (PD-1) or the PD-1 ligand inhibitors. Although rare, TTP is a life-threatening condition that could be challenging to diagnose, and early recognition is key as delayed treatment is associated with significant increase in mortality. The pathophysiology of immunotherapy-induced TTP is likely related to autoimmune inhibition of ADAMTS13; the addition of prednisone and rituximab to urgent plasmapheresis appears to be effective and should be part of the up-front management for these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13553","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T17:56:00Z","timestamp":1601920560000},"page":"1009-1012","source":"Crossref","is-referenced-by-count":18,"title":["Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy"],"prefix":"10.1093","volume":"25","author":[{"given":"Mansour","family":"Gergi","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara K.","family":"Landry","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ades","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Barry","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil A.","family":"Zakai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"},{"name":"Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Adrianzen","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"2021122511341768900_onco13553-bib-0001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"2021122511341768900_onco13553-bib-0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122511341768900_onco13553-bib-0003","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122511341768900_onco13553-bib-0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511341768900_onco13553-bib-0005","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2021122511341768900_onco13553-bib-0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: A systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"key":"2021122511341768900_onco13553-bib-0007","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00262-008-0627-x","article-title":"Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma","volume":"58","author":"Gordon","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"2021122511341768900_onco13553-bib-0008","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMc1110923","article-title":"Hemophilia A induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122511341768900_onco13553-bib-0009","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdx159","article-title":"Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma","volume":"28","author":"Bulbul","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511341768900_onco13553-bib-0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"The Oncologist"},{"key":"2021122511341768900_onco13553-bib-0011","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0224-7","article-title":"Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)","volume":"5","author":"King","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122511341768900_onco13553-bib-0012","first-page":"2464619","article-title":"Thrombotic thrombocytopenic purpura due to checkpoint inhibitors","volume":"2018","author":"Youssef","year":"2018","journal-title":"Case Rep Hematol"},{"key":"2021122511341768900_onco13553-bib-0013","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2021122511341768900_onco13553-bib-0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122511341768900_onco13553-bib-0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"2021122511341768900_onco13553-bib-0016","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1365-2141.2003.04049.x","article-title":"Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias","volume":"120","author":"Allford","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122511341768900_onco13553-bib-0017","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"2021122511341768900_onco13553-bib-0018","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/1009\/41919689\/oncolo_25_12_1009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/1009\/41919689\/oncolo_25_12_1009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:34:45Z","timestamp":1640432085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/12\/1009\/6443852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,10,23]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13553","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,10,23]]}}}